Company Profile
Vera Therapeutics Stock Price, News & Analysis
- Ticker:
- VERA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
32.02 USD (+5.50%)
Close
Last updated: August 6, 2026
2.24B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, VERA closed up 5.50% at $32.02. No new same-company headline was identified in the current news window.
Company overview
Kidney-Disease Biologics
Vera Therapeutics develops therapies for immune-mediated kidney diseases. Its lead program targets B-cell survival signals implicated in abnormal antibody production.
Atacicept
Atacicept is a recombinant TACI fusion protein that binds BAFF and APRIL. It is under Priority Review for accelerated approval in adults with IgA nephropathy.
Commercial Transition
Vera is preparing to move from clinical development into a commercial-stage model centered on atacicept, subject to FDA approval.
Future catalysts
FDA PDUFA target action date for atacicept on July 7, 2026.
Potential U.S. launch of atacicept around mid-2026, subject to approval.
Recent news
- 01
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Vera Therapeutics
- 02
- 03
- 04
- 05
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Source: Vera Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vera Therapeutics (VERA)?
Vera Therapeutics (VERA) most recently closed at 32.02 USD, a +5.50% move versus the previous session.
What is the market cap of Vera Therapeutics (VERA)?
Vera Therapeutics currently has a market capitalization of 2.24B USD on BioPharmSignal.
What does Vera Therapeutics do?
Kidney-Disease Biologics Vera Therapeutics develops therapies for immune-mediated kidney diseases. Its lead program targets B-cell survival signals implicated in abnormal antibody production. Atacicept Atacicept is a recombinant TACI fusion protein that binds BAFF and APRIL. It is under Priority Review for accelerated approval in adults with IgA...
On which exchange is VERA stock listed?
Vera Therapeutics (VERA) is associated with NASDAQ, United States, Biopharma.
What is atacicept?
FDA PDUFA target action date for atacicept on July 7, 2026.
Which conditions is Vera Therapeutics targeting with atacicept?
FDA PDUFA target action date for atacicept on July 7, 2026.
How does Vera Therapeutics describe recent progress with atacicept?
FDA PDUFA target action date for atacicept on July 7, 2026.
What is Kidney-Disease?
Kidney-Disease Biologics Vera Therapeutics develops therapies for immune-mediated kidney diseases.